AIM ImmunoTech Inc. (AIM): Multiplikator Forward P/S

AIM ImmunoTech generates stable income based on the uniqueness of the Ampligen drug. The expected price-to-sales ratio on the GURU.Markets daily chart confirms this trend, where the indicator level stands at 60.40. The therapy's independence from economic cycles guarantees business resilience, while the modernization of laboratories is currently preparing the company to increase the production volumes of new clinical series.

To assess the fundamental value of AIM ImmunoTech (AIM), investors must compare current market capitalization with projected sales volumes. Analyzing the forward P/S ratio allows for the tracking of market expectations prior to earnings releases, where an increase in this metric reflects confidence in the therapeutic potential of Ampligen, despite the ambiguous perception of the company among a broad circle of retail traders.